Is EXEL a good stock to buy now?
As of July 2026, Exelixis (EXEL) maintains a "Buy" consensus rating among analysts. The company's stock has demonstrated a strong multi-year performance record, supported by consistent revenue and cash flow from its oncology treatments. While some valuation metrics suggest the stock may be a bargain—trading at a P/E ratio lower than the broader biotech peer group—investors should consider that future upside will depend on continued clinical progress and the ability to navigate competitive pressures in the oncology market. As analyst ratings reflect professional sentiment rather than individual advice, you should conduct your own due diligence regarding the company's fundamentals and how the current price aligns with your portfolio strategy.
Related FAQs
Exelon Corporation, one of the largest utility companies in the United States, holds a generally stable reputation as a reliable provider of electricity to millions of customers.
Whether Exelixis (EXEL) is a good stock to buy is a decision that should be based on your personal investment objectives and risk appetite.
Based on the consensus of 14 analysts as of July 24, 2026, Exelixis (EXEL) holds a "Buy" rating. This professional sentiment is driven by the company's historical earnings performance and its role in the biotechnology sector.
Yes, Exelixis has demonstrated strong commercial performance and financial health, largely driven by its oncology drug Cabometyx [1.1.1].
Yes, Exelixis is a U.S.-based oncology biopharmaceutical company [1.2.1]. Founded in 1994 and headquartered in Alameda, California, its primary commercial and organizational operations are centered within the United States [1.2.1].